Engineered immune cells take on bone marrow cancer
NCT ID NCT03070327
First seen Mar 06, 2026 · Last updated May 07, 2026 · Updated 4 times
Summary
This early-phase trial tests a new treatment for multiple myeloma, a type of blood cancer. Doctors take a patient's own immune cells, modify them in the lab to recognize and attack cancer cells (BCMA-targeted CAR T cells), and give them back. The study also looks at combining these cells with a drug called lenalidomide. The main goal is to find the safest dose and check for side effects in up to 20 adults whose cancer has not responded to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.